Zhang Xiaoyan, Li Shenwei, Li Xinping, Li Xinxu, Xu Jianqing, Li Dongliang, Ruan Yuhua, Xing Hui, Zhang Xiaoxi, Shao Yiming
State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, China CDC, Beijing 100050, China.
AIDS. 2007 Dec;21 Suppl 8:S59-65. doi: 10.1097/01.aids.0000304698.47261.b1.
To characterize the HIV subtypes prevalent among men who have sex with men (MSM) in Beijing and to perform baseline genotypic analysis of anti-HIV drug resistance in this population.
In 2005, half of new HIV-1 infections occurred through unprotected sex in China. MSM have become the second most vulnerable group to HIV infection. HIV-1-prevalent subtypes among this population as well as their genetic and biological characteristics have not been well defined.
A cohort consisting of 54 HIV-seropositive MSM were recruited with written informed consent. Samples of plasma and whole blood were collected to characterize prevalent HIV-1 subtypes with overlapped polymerase chain reaction followed by sequencing and phylogenic analysis. The genotypes of anti-HIV drug resistance were analysed.
Among the amplified gag sequences, HIV-1 subtype B accounted for 71.1% (32/45), followed by CRF01_AE for 24.4% (11/45) and CRF07_BC for 4.4% (2/45). A similar trend was observed among the amplified env sequences. Six antiretroviral therapy (ART)-naive participants (15%) carried drug-resistant mutations, with intermediate to high-level resistance both to drugs used in China including zidovudine, didanosine, nevirapine, stavudine, and lamivudine, and drugs not used in China such as delavirdine, efavirenz, tenofovir, emtricitabine and abacavir. We also have concerns over nelfinavir and atazanavir regarding their future use in China because low-level resistance was also seen against those drugs.
The HIV-1 strains prevalent among Beijing MSM include complex subtypes derived from recombination. High rates of HIV drug-resistant mutations in ART-naive patients represent a serious challenge for HIV prevention and treatment programmes in China.
确定北京男男性行为者(MSM)中流行的HIV亚型,并对该人群的抗HIV药物耐药性进行基线基因型分析。
2005年,中国一半的新发HIV-1感染是通过无保护性行为发生的。MSM已成为第二大易感染HIV的群体。该人群中HIV-1流行亚型及其遗传和生物学特征尚未明确界定。
招募了54名HIV血清阳性的MSM组成队列,并获得书面知情同意。采集血浆和全血样本,采用重叠聚合酶链反应对流行的HIV-1亚型进行鉴定,随后进行测序和系统发育分析。对抗HIV药物耐药性的基因型进行分析。
在扩增的gag序列中,HIV-1 B亚型占71.1%(32/45),其次是CRF01_AE占24.4%(11/45),CRF07_BC占4.4%(2/45)。在扩增的env序列中观察到类似趋势。6名未接受抗逆转录病毒治疗(ART)的参与者(15%)携带耐药突变,对中国使用的药物包括齐多夫定、去羟肌苷、奈韦拉平、司他夫定和拉米夫定,以及中国未使用的药物如地拉韦啶、依非韦伦、替诺福韦、恩曲他滨和阿巴卡韦均有中到高水平耐药。我们也对奈非那韦和阿扎那韦在中国未来的使用表示担忧,因为对这些药物也观察到了低水平耐药。
北京MSM中流行的HIV-1毒株包括重组产生的复杂亚型。未接受ART治疗患者中HIV耐药突变的高发生率对中国的HIV预防和治疗计划构成了严峻挑战。